Chian Bio Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 9.26 Cr
as on 16-11-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.00 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit -60.60%
(FY 2023)
- Ebitda 67.80%
(FY 2023)
- Net Worth 15.94%
(FY 2023)
- Total Assets 118.25%
(FY 2023)
About Chian Bio
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.26 Cr.
The company currently has active open charges totaling ₹8.00 Cr.
Chidambarnathan Shanmuganathan, Dharani Chidambaranatham, Suman Chowdavaram, and One other member serve as directors at the Company.
- CIN/LLPIN
U74120TG2014PTC095095
- Company No.
095095
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Chian Bio?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suman Chowdavaram  | Director | 25-Mar-2021 | Current |
| Chidambarnathan Shanmuganathan | Director | 31-Jul-2014 | Current |
| Dharani Chidambaranatham | Director | 31-Jul-2014 | Current |
| Kumarasamy Sangitha | Director | 25-Mar-2021 | Current |
Financial Performance and Corporate Structure Insights of Chian Bio.
Chian Bio Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 60.6% decrease in profit. The company's net worth Soared by an impressive increase of 15.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chian Bio?
In 2023, Chian Bio had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sigachi Industries LimitedActive 35 years 11 monthsChidambarnathan Shanmuganathan is a mutual person
Pashamylaram Common Infrastructure Private LimitedActive 14 years 11 monthsChidambarnathan Shanmuganathan is a mutual person
- Pashamylaram Cetp Private LimitedActive 2 years 10 months
Chidambarnathan Shanmuganathan is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Jul 2022 | ₹8.00 Cr | Open |
How Many Employees Work at Chian Bio?
Unlock and access historical data on people associated with Chian Bio, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chian Bio, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chian Bio's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
